Dr. Grey AI

Sermorelin

Peptide

Sermorelin (GHRH 1-29) is a 29-amino-acid synthetic analog of growth hormone-releasing hormone (GHRH) that retains full biological activity. It was FDA-approved in 1990 for diagnostic use and in 1997 for treating childhood growth hormone deficiency. Sermorelin stimulates natural GH release from the pituitary gland through the hypothalamic-pituitary axis, producing physiological GH patterns with built-in safety through somatostatin feedback regulation.

Quick Answer

What it is

Sermorelin (GHRH 1-29) is a 29-amino-acid synthetic analog of growth hormone-releasing hormone (GHRH) that retains full biological activity. It was FDA-approved in 1990 for diagnostic use and in 1997 for treating childhood growth hormone deficiency.

Key findings

  • Grade A: Growth Hormone Release (Metabolic Health)
  • Grade A: IGF-1 Levels (Metabolic Health)
  • Grade A: Height Velocity (Children) (Bone Health)

Safety

No specific caution or interaction language was detected in the current summary/outcome notes.

⚠️ Research Notice

This peptide information is for educational and research purposes only. Peptides may not be FDA-approved for human use and may only be legally available for research purposes. Consult qualified healthcare professionals before considering any peptide compounds.

ℹ️ Quick Facts: Sermorelin

Quick Facts: Sermorelin

  • Best Evidence:Grade A
  • Conditions Studied:6
  • Research Outcomes:18
  • Grade A Findings:3
  • Grade B Findings:7
  • Key Effect:Metabolic Health
A3
B7
C7
D1
6 conditions · 18 outcomes

Detailed Outcomes

Grade:
Effect:
Size:
Sort:
|
A
Growth Hormone Release
Sermorelin nearly doubled 12-hour mean GH release in elderly men and elevated peak GH amplitude. Effects were sustained with the majority of GH release preserved at night in physiological patterns.
large↑Improves
A
IGF-1 Levels
Sermorelin elevated IGF-1 levels in elderly men in a dose-dependent manner, approaching levels seen in younger men. Elevations persisted for 2 weeks after stopping treatment.
moderate↑Worsens
B
Insulin Sensitivity
A significant increase in insulin sensitivity occurred in elderly men (P < 0.05) following 4 months of GHRH analog treatment, though not in women.
moderate↑Improves
A
Height Velocity (Children)
Sermorelin induced catch-up growth in GH-deficient children with significant increases in height velocity sustained during 12 months of treatment, with effects maintained for up to 36 months.
large↑Improves
B
Hormone Levels
54 human trials and systematic reviews support this finding. Evidence includes systematic reviews/meta-analyses. Human clinical trial data available.
moderate↑Improves
C
Anti-Cancer Activity
18 human trials support this finding. Human clinical trial data available.
moderate↑Improves
C
Anti-Inflammatory Activity
6 human trials support this finding. Human clinical trial data available.
small↑Improves
C
Pulmonary Function
5 preclinical studies support this finding. Primarily preclinical evidence.
small↑Improves
C
Cardiac Protection
4 human trials support this finding. Human clinical trial data available.
small↑Improves
C
Immune Function
3 human trials support this finding. Human clinical trial data available.
3 studies
small↑Improves
C
Cancer Cell Apoptosis
3 preclinical studies support this finding. Primarily preclinical evidence.
small↑Improves
C
Blood Glucose Control
3 preclinical studies support this finding. Primarily preclinical evidence.
small↓Improves
D
Corneal/Ocular Health
2 preclinical studies support this finding. Primarily preclinical evidence.
small↑Improves
B
Lean Body Mass
GHRH analog treatment significantly increased lean body mass in elderly men (P < 0.05) in a 4-month randomized controlled trial.
moderate↑Improves
B
Muscle Strength
Six weeks of nightly sermorelin led to significant improvements in 2 of 6 muscle strength tests and the abdominal crunch muscle endurance test in elderly men.
small↑Improves
B
Skin Thickness
A significant increase in skin thickness was observed in both elderly men and women following 4 months of GHRH analog treatment.
moderate↑Improves
B
General Well-Being
Quality of life parameters showed significant improvement in general well-being (P < 0.05) and libido (P < 0.01) in elderly men following 4 months of treatment.
moderate↑Improves
B
Cognitive Function
Six months of GHRH treatment improved performance on tests of fluid intelligence including working memory, planning, selective attention, and processing speed in healthy older adults.
small↑Improves

Research Citations (47)

Growth Hormone-Releasing Hormone Antagonists Increase Radiosensitivity in Non-Small Cell Lung Cancer Cells.
(2025)
PMID: 40244089
Growth hormone-releasing hormone receptor antagonist MIA-602 attenuates cardiopulmonary injury induced by BSL-2 rVSV-SARS-CoV-2 in hACE2 mice.
(2023)
PMID: 37983492
Growth hormone-releasing hormone antagonist MIA-602 inhibits inflammation induced by SARS-CoV-2 spike protein and bacterial lipopolysaccharide synergism in macrophages and human peripheral blood mononuclear cells.
(2023)
PMID: 37649486
GHRH agonist MR-409 protects β-cells from streptozotocin-induced diabetes.
(2023)
PMID: 37307472
Synthesis of potent antagonists of receptors for growth hormone-releasing hormone with antitumor and anti-inflammatory activity.
(2022)
PMID: 34952135
Impact of growth hormone-releasing hormone antagonist on decidual stromal cell growth and apoptosis in vitro†.
(2022)
PMID: 34792103
Growth hormone-releasing hormone agonists ameliorate chronic kidney disease-induced heart failure with preserved ejection fraction.
(2021)
PMID: 33468654
Effects of growth hormone-releasing hormone agonistic analog MR-409 on insulin-secreting cells under cyclopiazonic acid-induced endoplasmic reticulum stress.
(2021)
PMID: 34252492
Growth hormone secretagogues: history, mechanism of action, and clinical development
(2020)
PMID: 31694394
Antinflammatory, antioxidant, and behavioral effects induced by administration of growth hormone-releasing hormone analogs in mice.
(2020)
PMID: 31959947

Related Peptides

Tesamorelin

Peptide

3 shared conditions · 15 outcomes

Tesamorelin is a 44-amino-acid synthetic analog of growth hormone-releasing hormone (GHRH) that is FDA-approved (2010) for reducing excess abdominal fat in HIV-infected patients with lipodystrophy. It stimulates endogenous pulsatile GH secretion from the pituitary gland. Tesamorelin has demonstrated efficacy in reducing visceral adipose tissue, liver fat (NAFLD), and improving cognitive function in clinical trials.

Ipamorelin

Peptide

3 shared conditions · 9 outcomes

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that acts as a selective growth hormone secretagogue. It stimulates growth hormone release from the pituitary gland by binding to the ghrelin/GHSR-1a receptor, with notable selectivity that does not significantly affect ACTH or cortisol levels, distinguishing it from other growth hormone releasing peptides.